{
    "clinical_study": {
        "@rank": "40343", 
        "arm_group": {
            "arm_group_label": "recurrent T1-2 NPC,no treatment", 
            "arm_group_type": "Experimental", 
            "description": "3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT"
        }, 
        "brief_summary": {
            "textblock": "The hypothesis of the study is to address the efficacy and toxicity profile of\n      aforementioned four modalities for rT1-2 NPC.\n\n      Characters of the patients:\n\n        -  list item one: 168 patients, median age 48 years (range 16-75 years\uff09 proven rT1-2 NPC\n           were diagnosed\n\n        -  list item two: Treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT\n           Combined 3D-CRT or IMRT).\n\n        -  list item three: Median time to recurrence was 30 months (range 1-180months). The\n           median follow-up time was 28 months (range, 4-135 months)."
        }, 
        "brief_title": "Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": "Nasopharyngeal Cancer Recurrent", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives:\n\n      Recurrent T1-2 Nasopharyngeal Carcinoma (rT1-2) may be salvaged by 3D - CRT\uff083D-Conformal\n      Radiotherapy\uff09, IMRT\uff08 Intensity Modulated Radiotherapy\uff09, Brachytherapy (BT), BT combined 3D -\n      CRT or IMRT . The aim of this study is to address the efficacy and toxicity profile of\n      aforementioned four modalities for rT1-2 NPC.\n\n      Methods and Materials:\n\n      168 patients, median age 48 years (range 16-75 years\uff09 proven rT1-2 NPC were diagnosed and\n      treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or\n      IMRT) . Median time to recurrence was 30 months (range 1-180months). The median follow-up\n      time was 28 months (range, 4-135 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  recurrent T1-2 nasopharyngeal carcinoma patients\n\n        Exclusion Criteria:\n\n          -  non recurrent T1-2 nasopharyngeal carcinoma patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113423", 
            "org_study_id": "FJCH009911"
        }, 
        "intervention": {
            "arm_group_label": "recurrent T1-2 NPC,no treatment", 
            "description": "3D - CRT\uff083D-Conformal Radiotherapy\uff09: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT\uff08Intensity Modulated Radiotherapy\uff09: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID*2F", 
            "intervention_name": "3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "superiority, re-irradiation, IMRT, recurrent T1-2 NPC", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fuzhou", 
                    "country": "China", 
                    "state": "Fujian", 
                    "zip": "350014"
                }, 
                "name": "Fujian Cancer Hospital Radiation Oncology Department"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Superiority of Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma", 
        "overall_official": {
            "affiliation": "Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China", 
            "last_name": "Jianji Pan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "all cause mortality", 
            "safety_issue": "No", 
            "time_frame": "thirteen years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fujian Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fujian Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1996", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}